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1. Describe the presenting signs and 
symptoms associated with Lower Urinary 
Tract Symptoms.
2. Describe the various methods used in the 
initial evaluation of  LUTS.
3. Understand the natural history of LUTS/BPH 
and complications based on progression.
4. Be aware of the various treatment 
modalities for LUTS and the appropriate 
context in which they are used.      
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 Lower urinary tract symptoms (LUTS) secondary to BPH 
(LUTS/BPH)
 Lower urinary tract symptoms independent of BPH
 Overactive bladder syndrome-urgency w or w/o urge incontinence, 
usually with frequency and nocturia
 Bladder outlet obstruction (BOO)- generic term for all forms of 
obstruction
 Benign Prostatic Hyperplasia (BPH)-pathological term
 Detrusor overactivity-urodynamic term
 Benign prostatic obstruction (BPO)- pressure flow studies term
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 An increase in the 
numbers of stromal 
cells in the 
transition zone of 
the prostate
 An increase in  the  
number of alpha-1-
receptors
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 Interference with activities of daily 
living
 Interference with psychological 
well being
 Interference with sleep
These materials provided for reference use at the 43rd Annual Family Medicine Refresher Course for the Family Physician. 
Permission from the author must be sought before reuse or redistribution.
0
10
20
30
40
50
60
70
80
90
100
<30 31-40 41-50 51-60 61-70 71-80 81-90+
BPH 
These materials provided for reference use at the 43rd Annual Family Medicine Refresher Course for the Family Physician. 
Permission from the author must be sought before reuse or redistribution.
 Prostate growth is dependent on:
◦ Time (aging)
◦ Presence of androgen (primarily 
Testosterone)
◦ Dihydrotestosterone (DHT) – concentrated 
intranuclearly primarily in prostatic stromal 
cells
 Resistance is increased by:
◦ Prostate volume
◦ Alpha-1 adrenergic stimulation-
concentrated in prostatic smooth muscle at 
bladder neck
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*Degree of bladder outlet obstruction 
doesn’t  always correlate with severity of 
symptoms
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Obstructive (Voiding) 
 Weak stream 
 Prolonged micturition 
 Straining 
 Hesitancy 
 Intermittent stream 
 Feeling of incomplete 
bladder emptying
Irritative (Storage)
 Frequency 
 Nocturia 
 Urgency 
 Incontinence
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 Urinary retention 
 Renal impairment 
 Urinary tract infection
 Gross hematuria 
 Bladder stones 
 Bladder damage 
(trabeculations, cellules, 
diverticula)
 Urge/overflow 
incontinence
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 History and  AUA symptom score
 Physical examination
 Including DRE and neurological evaluation
 Urinalysis, Urine culture
 Creatinine, BUN (with high PVR- not routinely 
recommended)
 PSA (as appropriate)
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Symptom
 Incomplete emptying
 Frequency
 Intermittency
 Urgency
 Weak stream
 Straining
 Nocturia: number of 
events per night (0-5)
Scale 
0 - Not at all
1 - Less than 1 time in 5
2 - Less than half the 
time
3 - About half the time
4 - More than half the 
time
5 - Almost always
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Classification
Mild
Moderate
Severe
AUA-SI Score
0-7
8-19
20-35
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 Increases detection rate for prostate cancer 
over DRE alone
 Age range PSA values (ng/ml)
40-49 0.00-2.50
50-59 0.00-3.50
60-69 0.00-4.50
70-79 0.00-6.50 
 Nonspecific for prostate cancer 
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Objective diagnostic data
 PVR
 Uroflow/BVI  (urinary flow/pressure study)
 Cystoscopy 
 Urodynamic Studies 
 Transrectal ultrasound
 Urine cytology (irritative symptoms) 
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 BPH
 Overactive bladder 
 Prostate cancer 
 Bladder cancer 
 Urinary tract infection 
 Urethral stricture 
 Neurogenic bladder — neurologic conditions
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 Patient history, physical exam and 
appropriate laboratory tests for initial 
evaluation 
 Differential diagnosis and rule out prostate 
cancer 
 Assess risk of LUTS/BPH-related outcomes 
 Discuss treatment options
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 What are the differences in treating men vs 
women? 
 How common are UTIs in older men? 
 How do you decide to treat if not 
symptomatic? 
 When and how to use UA/micro/culture?
 What are the common organisms? 
 Are there new resistant organisms arising 
that make treatment more difficult?
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 Alleviate bothersome symptoms
 Alteration of disease progression
 Prevent complications (AUR, surgery)
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 Avoid substances that 
exacerbate symptoms 
or cause retention
• A-agonists
• Decongestants-
pseudoephedrine 
• Diet supplement-ephedra
• Anticholinergics
• Caffeine, Alcohol, spicy, 
acidic foods
 Reduce nocturia
• Decrease evening fluid 
intake
• Avoid diuretics in the 
evening
• If lower extremity edema, 
elevate legs one hour before 
bedtime
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 Watchful waiting
 Phytotherapy
 Medical therapy
 Minimally invasive procedures
 Surgery
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 Minimal symptoms 
 Decision not to undergo further treatment 
now 
 Monitor clinical course
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 Saw palmetto (Serenoa repens)
 African plum (Pygeum 
africanum) 
 Stinging nettle (Urtica dioica) 
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• Alpha-adrenergic receptor blockers
• Cardura®  (doxazosin mesylate) 
• Hytrin®    (terazosin hydrochloride)
• Uroxatral® (alfuzosin hydrochloride)
• Flomax®  (tamsulosin hydrochloride)*
• Rapaflo® (silodosin hydrochloride)*
*Selective
• Type II 5-α reductase inhibitors 
• Proscar® (finasteride) 
• Avodart® (dutasteride)
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Combination Therapy
Alpha blocker and 5-alpha-reductase inhibitor
 Jalyn® (dutasteride/tamsulosin)
Alpha blocker and anticholinergics
Anticholinergic Agents
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Relaxes prostate and bladder 
neck smooth muscle tone
Significant improvement in 
symptom scores and flow rate
Improves symptoms rapidly
No change in PSA or prostate 
size
Not indicated to reduce 
incidence of AUR or TURP
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Dose dependent improvement in urinary 
symptoms score and maximum urinary flow rate
• Near max improvement in urinary flow rate
• Within 8 hours (selective blockers)
• May take 2-4 weeks (non-selective)
•
• Near maximum in voiding symptoms 
• May take 1-3 months for all 
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AUA 2010 Guideline Recommendations
 Men with LUTS/BPH for whom alpha-blocker 
therapy is offered should be asked about planned 
cataract surgery. Men with planned cataract 
surgery should avoid the initiation of alpha-
blockers until their cataract  surgery is completed
 In men with no planned cataract surgery, there are 
insufficient data to recommend withholding or 
discontinuing alpha blockers for bothersome 
LUTS/BPH 
*More common with selective alpha blockers 
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 Asthenia 
 Postural 
hypotension
 Dizziness 
 Nasal congestion/ 
rhinitis    
 Abnormal 
ejaculation
 Fatigue 
 Somnolence 
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Testosterone
 Specific inhibitor of the Type II 5‐a‐reductase enzyme
 Significant decrease in serum and prostatic DHT 
 Testosterone remains in normal physiologic range
 PSA and Prostate size decreases
5-a reductase DHT
Testosterone
5-a reductase
DHT
Type II 5-a reductase inhibitors
X
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 Significantly reduces AUR 
 Significantly reduces BPH-related surgery 
 Significantly improves symptoms and flow rates 
yearly (>4 years)
 Achieves and maintains reductions in prostate 
volumes over 4 years
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 Impotence 
 Decreased libido 
 Decreased ejaculate 
 Ejaculation disorder 
 Breast enlargement 
 Breast tenderness 
 Rash and hypersensitivity 
reaction 
 Testicular pain
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 Approximate 50% decrease in PSA 
(may vary in individual patients) 
 Therefore: Double PSA value in patients treated 
6 months or more for comparison with normal 
ranges 
 Percent free PSA unaffected 
 Any sustained increase in PSA levels for patients on 
Type II 5-a reductase inhibitors: should be 
carefully evaluated
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 The effects of finasteride on prevention of 
prostate cancer were evaluated in a large, 
randomized, placebo controlled study in men 
considered at increased risk for prostate 
cancer, and a statistically significant increase 
in the incidence of higher grade prostate 
cancer (Gleason score ≥7) was found in men 
who received finasteride (Thompson 2003; 
Thompson 2013).
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Combination of finasteride and doxazosin
 Reduced disease progression by 66% compared to 
placebo (39% doxazosin alone, 34% finasteride 
alone)
 Greater symptom relief & improvement in urinary 
flow rate
 Reduced risk of invasive  therapy by 67% compared 
(64% finasteride)
Especially effective- Prostate>40 ml or PSA >4 ng/ml
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Overactive Bladder (OAB) and BPH often coexist
 Generally treat BPH/LUTS first 
 Antimuscarinic therapy shown effective in men
 Tolterodine shown no increased risk of AUR
 Monitor PVR (post void residual) in men at risk for AUR
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 Oxybutynin (Ditropan, Ditropan XL, Oxytrol patch, Gelnique gel 
& generic)
 Darifenacin (Enablex)
 Fesoterodine (Toviaz)
 Tolterodine (Detrol, Detrol LA)
 Trospium (Sanctura, Sanctura XR
 Solifenacin (Vesicare)
* Side effects- dry mouth,  constipation, dry eyes, blurred vision,  
dizziness, urinary hesitancy, urinary retention, confusion, falling, 
drowsiness
 Mirabegron (Myrbetriq) beta-3 adrenergic agonist
 Botox
 Interstim
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Clean intermittent catheterization 
(CIC) 
◦ Lower incidence/ risk of urine infection 
compared to an indwelling urinary catheter
◦ Prophylactic antibiotics not recommended
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 Acute retention of urine 
 Chronic retention due to prostatic 
obstruction 
 Recurrent urinary tract infection/hematuria 
 Bladder stones secondary to BPH 
 Renal insufficiency due to BPH 
 Large bladder diverticulum/ diverticula 
 Patient preference
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 Laser (Nd:YAG, Holmium) 
 Transurethral electrovaporization of the 
prostate (TUEVP) 
 Microwave thermotherapy (TUMT) 
 Radio frequency applications (TUNA) 
 High-Intensity focused ultrasound (HIFU) 
 Urethral stents (Urolume)
Long-term efficacy unknown in comparison to TURP
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•Transurethral Resection of the Prostate 
(TURP) 
 Common form of surgical intervention 
 Highly efficacious
•Transurethral Incision of the Prostate 
(TUIP) 
•Open Prostatectomy 
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 LUTS/BPH is a common disease with 
potentially  serious outcomes 
 As the population ages, LUTS/BPH will be an 
increasing medical concern for physicians
 Evaluation of the prostate/urinary symptoms 
in older men should be part of routine office 
practice
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Antimicrobial Therapy for the Treatment of Urinary Tract Infection and Prostatitis in Men.
Schaeffer AJ, Nicolle LE. N Engl J Med 2016;374:562-571
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